THE SYNthesis, CHARACTERIZATION, AND ELECTROCHEMICAL STUDY OF TRIS(PYRAZOLYL)-TYPE IRON(II) COMPLEXES, IRON(II) SULFUR- AND SELENIUM-CONTAINING COMPLEXES, AND TRIS(PYRAZOLYL)-TYPE RUTHENIUM(II) COMPLEXES by Underwood, Christopher
Clemson University
TigerPrints
All Theses Theses
12-2010
THE SYNthesis, CHARACTERIZATION, AND
ELECTROCHEMICAL STUDY OF
TRIS(PYRAZOLYL)-TYPE IRON(II)
COMPLEXES, IRON(II) SULFUR- AND
SELENIUM-CONTAINING COMPLEXES,
AND TRIS(PYRAZOLYL)-TYPE
RUTHENIUM(II) COMPLEXES
Christopher Underwood
Clemson University, EZ1908@gmail.com
Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Chemistry Commons
This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Underwood, Christopher, "THE SYNthesis, CHARACTERIZATION, AND ELECTROCHEMICAL STUDY OF
TRIS(PYRAZOLYL)-TYPE IRON(II) COMPLEXES, IRON(II) SULFUR- AND SELENIUM-CONTAINING COMPLEXES,
AND TRIS(PYRAZOLYL)-TYPE RUTHENIUM(II) COMPLEXES" (2010). All Theses. 1006.
https://tigerprints.clemson.edu/all_theses/1006
i 
 
 
 
 
 
 
 
THE SYNTHESIS, CHARACTERIZATION, AND ELECTROCHEMICAL STUDY OF 
TRIS(PYRAZOLYL)-TYPE IRON(II) COMPLEXES, IRON(II) SULFUR- AND 
SELENIUM-CONTAINING COMPLEXES, AND TRIS(PYRAZOLYL)-TYPE 
RUTHENIUM(II) COMPLEXES 
 
 
A Thesis 
Presented to 
the Graduate School of 
Clemson University 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
Chemistry  
 
 
by 
Christopher Cole Underwood 
September 2010 
 
 
Accepted by: 
Dr. Julia L. Brumaghim, Committee Chair 
Dr. William T. Pennington 
Dr. Rhett C. Smith 
  
 
 ii
ABSTRACT 
 
 
Highly reactive radical species such as hydroxyl radical cause oxidative stress, 
resulting in chronic or degenerative diseases.  In the biological Fenton reaction, iron(II) 
generates hydroxyl radical, OH, but only within a specific electrochemical potential 
window (-324 mV to 640 mV).  Selenium and sulfur compounds have been extensively 
studied for their antioxidant properties, and they may exert their effects by binding 
iron(II) and shifting its electrochemical potential out of this window.  This work has 
investigated the synthesis and electrochemical characterization of iron(II) chalcogenate 
complexes and iron(II) chalcogenone complexes.  Cyclic voltammetry (CV) of 
[Fe(EPh)4][(PPh4)2] (E = S, Se) complexes shows Fe2+/3+ redox potentials of -723 mV (E 
= S) and -1010 mV (E = Se) vs. NHE.  These electrochemical results suggest that 
selenium coordination stabilizes iron(II) relative to sulfur coordination and may inhibit 
iron redox cycling. 
  Because of synthetic difficulties with iron(II) complexes, ruthenium(II) was 
substituted for iron(II) due to its inert reaction kinetics and diamagnetism, allowing the 
use of NMR spectroscopy for characterization. Tris(pyrazolyl)methane ruthenium(II) 
complexes of the formula [TpmRRu(NCCH3)3]2+ (R = Me, Ph) and the previously-
reported tris(pyrazolyl)borate ruthenium(II) complexes [TpRRu(NCCH3)3]+ (R = H, Me, 
Ph) have been synthesized using a new synthetic pathway that reduces the number of 
required steps on average by 80% and average reaction times by over 95%.  
Tris(pyrazolyl) (Tp) ligands are used to mimic adenine and guanine coordination to 
ruthenium(II), known sites of metal localization.  CV studies of [TpRu(NCCH3)3][BF4] 
 iii 
(Tp = tris(pyrazolyl)borate) and [Tp*Ru(NCCH3)3][OTf] (Tp* = tris(3,5-
dimethylpyrazolyl)borate) determined Ru2+/3+ redox potentials of 489 mV and 498 mV, 
respectively, vs. NHE compared to the Ru2+/3+ redox potential for [Ru(NCCH3)6][(BF4)2] 
of 517 mV.  Thus, coordination of Tp-type ligands substantially affects the redox 
chemistry of ruthenium as well as iron.  
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CHAPTER ONE 
 
A BRIEF REVIEW OF THE USES OF IRON AND RUTHENIUM COMPLEXES 
WITH TRIS(PYRAZOLYL) LIGANDS AND THEIR BIOLOGICAL RELEVANCE  
 
Introduction 
Iron is an essential metal that is required for the activity of enzymes and proteins.  
It is vital in the transport O2 throughout mammalian organisms in hemoglobin,1 in the 
electron transport chain of cellular respiration in cytochrome,2 and the degradation of 
hydrogen peroxide into oxygen and water in catalase.3  As a transition metal, non-
protein-bound iron is prone to electron transfer reactions that enable it to generate 
reactive oxygen species (ROS).  This labile iron participates in the Fenton reaction 
generating the ROS hydroxyl radical, OH (Figure 1.1).  Labile iron(II) generates OH by 
reducing hydrogen peroxide (a byproduct of cellular respiration), thereby oxidizing iron 
from a +2 oxidation state to +3.  Iron(III) is then reduced back to iron(II) by cellular 
reductants such as nicotinamide adenine dinucleotide (NADH) to complete the cycle.4   
   
 
Figure 1.1.  The Fenton reaction in biological systems. 
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The generated hydroxyl radical can cause oxidative stress in cells, damage to 
lipids and proteins, and damage to DNA.5  Hydroxyl radical has been identified as a 
primary cause of increased risk of life-threatening and chronic or degenerative diseases 
such as cancer,6 as well as cardiovascular,7 Alzheimer’s,8 and Parkinson’s diseases8-12 
and is a primary factor in the aging process.13 Therefore, it is of great interest to 
investigate methods to prevent the formation of hydroxyl radical for disease prevention 
and treatment. 
Many types of DNA modifications are caused by OH,14,15 and several of the OH-
induced DNA modifications are mutagenic.16  DNA damage from hydroxyl radical 
occurs at the nucleotide bases and the phosphate backbone via strand breakage.17  In 
cells, positively-charged iron ions localize around the negatively-charged phosphate 
backbone to help stabilize the charge of the oxygen atoms18 and electron-rich nucleotide 
bases (specifically at guanine-rich sequences)19-21 through electrostatic interactions 
(Figure 1.2).  When hydrogen peroxide is in close proximity to localized iron(II) on the 
DNA phosphate backbone, OH is formed and can deprotonate the backbone at the 4’ 
carbon, resulting in a rearrangement reaction that ultimately cleaves the phosphodiester 
bond between deoxyribose sugars and DNA backbone cleavage.18,19,21,22 
N,N,N-type donor ligands have been of interest in metalloenzyme modeling, 
specifically with 2-His-1-carboxylate functionality (Figure 1.3) commonly found in 
enzymes that contain non-heme iron(II).23  These ligands coordinate a wide variety of 
metal centers, specifically late 1st row transition metals.  Two widely used ligands of the  
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Figure 1.2.  (A, left) NMR structure of ATGA segment (red) from DNA showing Fe2+ 
(orange) bound to the N7 of the guanine base and its proximity to the cleaved thymidine 
deoxyribose (yellow), used with permission.20  (A, right) Fe2+ binding to an ATGA 
segment, drawn for clarity.  (B, left) NMR structure the AGGG segment (A in green and 
GGG in pink) from DNA showing Fe2+ (orange) bound to the N7 of the guanine bases 
and its proximity to the cleaved thymidine deoxyribose (yellow), used with permission.22  
(B, right) Fe2+ binding to an AGGG segment, drawn for clarity. 
 
A 
B 
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N,N,N-type are tris(pyrazolyl)borates (TpR; 1; Figure 1.4) and tris(pyrazolyl)methanes 
(TpmR; 2; Figure 1.4).   First synthesized by Trofimenko, Tp and Tpm coordinate to 1st   
and 2nd row transition metals, and the properties of these complexes have been 
extensively studied in terms of structural characterization, reactivity, and electronic 
properties.24 Trofimenko and Kitajima have used tris(pyrazolyl)borate (Tp) complexes 
with N,N,N donor ligands to model several enzymes with the 2-His-1-carboxylate facial 
triad; however, there were drawbacks in terms of lack of O donation from the ligand, 
since the O donor increases the stability of the scaffold.25-31  These trinitrogen donor 
ligands are widely used in the synthesis of biometallic complexes due to their similar 
reactivities to the cyclopentadienyl (Cp) family of ligands, especially when bound to 
iron.32  No previous reports using Tp-type ligands as DNA coordination mimics exist, but 
it is believed these ligands can be used to mimic metal binding to adenine and guanine 
N7, known sites of metal localization (Figure 1.2).33 
 
FeII
O
Y
X Z
N
NH
N NHO
 
Figure 1.3.  Model of the 2-His-1-carboxylate functionality using non-heme iron(II); X, 
Y, and Z represent open coordination sites.   
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Figure 1.4. Structures of tris(pyrazolyl)borate (TpR) and tris(pyrazolyl)methane (TpmR) 
ligands. 
 
 A useful property of the N,N,N-type ligands is the ability to tune both their 
electronic properties, by using a neutral ligand (TpmR) or negatively-charged ligand 
(TpR), and to tune their steric properties by adding the desired R substituents to control 
steric bulk.  This ability has led to widespread applications of TpR and TpmR ligands in 
metalloenzyme model chemistry,29 polymerization catalysis,34 C-H bond activation,35 and 
metal ion extraction.36  There also is intrinsic interest in the electronic characteristics of 
TpR and TpmR ligands relative to those of other facially-coordinating, six-electron donors 
such as 1,4,7-triazacyclononane (TACN) and cyclopentadienyl (Cp) ligands.37,38 
 
Tp-Type Iron Chemistry and Its Applications 
 Tp-type iron complexes have been extensively studied since they were first 
synthesized by Trofimenko in 1966.39  One of these types of complexes are the 
octahedral Tp2Fe (1) and Tp*2Fe (2; Figure 1.5) that can be formed in high yields using 
iron(II) salts such as FeCl2, Fe(OAc)2, and Fe(OTf)2 with two equivalents of the desired 
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TpR ligand.  These iron(II) complexes have displayed unusual temperature-dependent 
spin-state crossover behavior.40-45  
 Another type of complex includes oxo-bridged diiron centers, such as Tp2Fe2(µ-
O)(µ-O2CCH3), (3; Figure 1.5) that resembles metalloenzymes such as hemerythrin, 
rubrerythrin, and methane momo-oxygenase.  The crystal structure of 3 shows iron 
coordination by one µ-oxo and two µ-carboxylato bridges with the Tp ligand mimicking 
three histidine moities.46  The five-coordinate iron(III) complex TpiPrFe(OAc) (4; Figure 
6) was also synthesized and acts as a mimic for non-heme metalloprotein hemoglobin and 
cytochrome P-450.47  Facially-capped Tp-type iron complexes are also of interest as 
synthons for magnetic materials.  Iron(III) complexes of the type (R = H, Me, iPr; 5; 
Figure 1.6) have been synthesized and studied for their electrical and optical properties, 
but mostly for their ability to self-assemble into bridged chains that have exhibited 
unusual magnetic properties.48,49  
 Tris(pyrazolyl)methane iron complexes have also been studied since they were 
first synthesized by Trofimenko,50 but not as extensively as analogous 
tris(pyrazolyl)borate iron complexes.  Iron complexes of Tpm such as [Tpm2Fe][X2] (X = 
BF4-, ClO4-, OTf-; 6; Figure 1.7) can be formed in high yields using iron(II) salts such as 
Fe(BF4)2, Fe(ClO4)2, and Fe(OTf)2 with two equivalents of the desired Tpm ligand.  
These iron(II) complexes have also displayed unusual temperature-dependent spin-state 
crossover behavior similar to that of their Tp2Fe analogs.51 
 Similarly, Tpm-type iron complexes of considerable interest are the facially- 
capped synthons.  One example are the complex [Tpm*Fe(NCE)2(NCCH3)] (E = S, Se;  
 7
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Figure 1.5. Structures of Tp2Fe (R = H, 1), Tp*2Fe (R = Me, 2, top), and Tp2Fe2(µ-O)(µ-
O2CCH3) (3, bottom).  
 
 
N
N N
N
N
N
H
B
Fe
O O
N
N N
N
N
N
R
R
R
R
R
R
H
B
Fe
NC CN
CN
NEt4
 
Figure 1.6.  Structures of TpiPrFe(OAc) (4, left) and [NEt4][TpRFe(CN)3] (R = H, Me, 
iPr; 5, right).  
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Figure 1.7. Structure of [Tpm2Fe][X2] (X = BF4-, ClO4-, OTf-; R = H, CH3, iPr; 6). 
 
9; Figure 1.8) which were studied for spin-crossover behavior and found to be 
comparable to that of their bis-Tpm analogs.52 Another complex, 
[Tpm*Fe(NCCH3)3][(BF4)2] (10; Figure 1.8), was synthesized and tested to determine if 
it could generate a nine-membered triphosphorous macrocycle via intramolecular 
hydrophosphination.  The complex was treated with bidentate phosphines such as 1,2-
diphosphinoethane in tetrahydrofuran (THF), and was found to undergo ligand 
disproportionation to form [Tpm*2Fe][(BF4)2] and the tris-diphosphino iron(II) species 
(Scheme 1).32 
 
Tp-Type Ruthenium Chemistry and Its Applications 
 Ruthenium is in the same group as iron, but it is a soft, inert metal unlike  
borderline, labile iron(II).  Ruthenium(II) is diamagnetic, unlike its paramagnetic iron(II) 
cousin, making NMR data evaluation of ruthenium(II) complexes more tractable 
compared to iron(II).  These properties make ruthenium(II) ideal for coordination studies 
related to iron(II). 
 Tp-type ruthenium(II) complexes also have practical uses outside of being  
 9
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Figure 1.8.  Structures of [Tpm*Fe(NCE)2(NCCH3)] (E = S, Se; 7, left) and 
[Tpm*Fe(NCCH3)3][(BF4)2] (8, right). 
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suitable substitutes for iron(II) such catalysis applications, but they have mostly been 
limited to the parent Tp ligand.  One example is Tp2Ru (analogous to the iron complex in 
Figure 1.5), synthesized by combining the thallium salt of Tp with 
tetrakis(benzonitrile)dichlororuthenium(II) in benzene and heating to reflux for two days 
before column chromatographic purification.  The bis-Tp complex was used as in the 
catalytic hydrogenation of olefins such as methyl acrylate.53  Surprisingly, this complex is 
the only reported bis-Tp ruthenium complex of any kind. 
 Another more widely used complex is TpRuCl(COD) (COD = cyclooctadiene; 9; 
Figure 1.9), synthesized by heating the polymeric [RuCl2(COD)]n with KTp to reflux in 
THF.54  This Tp-type COD-containing complex has been used as a catalyst in the 
reactions of phenylacetylene with allyl alcohols to form selective C-O coupled products55 
and trimethylsilylacetylene with allyl alcohols to form an (allyloxy)carbenes.56  Another 
ruthenium complex, TpRu(R)(NCCH3)Me (R = CO, PMe3; 10; Figure 1.9), activates C-H 
bonds in the presence of furan or thiophene to produce methane and TpRu(NCCH3)(aryl) 
(aryl = 2 furyl or 2-thienyl)57 and to activate sp3 C-H bonds to form new C-C and C-N 
bonds when heated in excess acetone or acetonitrile, respectively.58  Tp*RuH(COD) (11; 
Figure 1.9) was generated from RuHCl(COD)(Bpm) (Bpm = bis(pyrazolyl)methane) and 
KTp* in hopes of producing a saturating species that could activate C-H bonds or 
perform hydrogen transfer reactions.59 
The Tp-type ruthenium complexes of the formula [TpRRu(NCCH3)3][X] (R = H, 
Me, iPr; X = PF6-, OTf-) are of great interest, since these would make excellent synthons 
for a variety of ruthenium chemistry.  [TpRu(NCCH3)3][PF6] (12; Figure 1.10) was 
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synthesized by heating TpRuCl(COD) and NH4PF6 in a 1:1 mixture of dichloromethane 
and dimethylformamide to reflux and was originally used to study ligand exchange 
kinetics of its acetonitrile ligands in comparison to the analogous [CpRu(NCCH3)3]+.60  
[Tp*Ru(NCCH3)3][OTf] (13; Figure 1.10) was prepared by stirring Tp*RuH(H2)2 with 
triflic acid at -80 °C in THF, and was created as a byproduct when determining the 
strength of acid needed to create H2 gas from the Ru(II) starting material.61  
[TpiPrRu(NCCH3)3][OTf] (14; Figure 1.10) was synthesized by stirring 
[TpiPrRu(OH2)2(THF)][(OTf)(THF)2] in acetonitrile.62 
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Figure 1.9.  Structures of TpRuCl(COD) (9, top), TpRu(R)(NCCH3)Me (R = CO, 
P(CH3)3; 10, middle), and Tp*RuH(COD) (11, bottom). 
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Figure 1.10.  Structures of [TpRRu(NCCH3)3][X] (R = H, X = PF6-, 12; R = Me, X = 
OTf-, 13; R = iPr, X = OTf-, 14). 
 
 
Unlike Tp-type ruthenium complexes, reports of Tpm-type ruthenium complexes 
are rare.  One complex, fac-[TpmRu(DMSO-S)2(DMSO-O)][(OTf)2] (15; Figure 1.11), 
was made by heating fac-[Ru(DMSO-O)3(DMSO-S)3][(OTf)2] with Tpm in methanol to 
reflux.  But unlike its Tp-type ruthenium analogs, only two of the three pyrazole rings 
coordinate to the metal center, as proven through X-ray crystallography.63  Another 
reported complex, [TpmRu(OH2)3][(OTs)2] (16; Figure 1.11), was synthesized by 
cleaving the diruthenium species Tpm2Ru2(OH)(µ-O)(µ-O2PO) with tosylic acid in an 
aqueous solution in hopes to form dioxygen through electrooxidation of the ruthenium 
center.64 
 The most relevant Tpm-type ruthenium(II) complex pertaining to this work is 
[TpmRuCl(NCCH3)2][PF6] (17; Figure 1.12).  It is believed that with two weakly-
coordinated acetonitrile solvato ligands, this complex would be a valuable synthon to 
perform subsequent ruthenium chemistry.  This Tpm-ruthenium(II) complex was 
synthesized by heating the ruthenium(III) species TpmRuCl3 to reflux with Zn dust in 
acetonitrile, followed by a counterion exchange with NH4PF6.65 
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Figure 1.11.  Structures of fac-[TpmRu(DMSO-S)2(DMSO-O)][(OTf)2] (15, top) and 
[TpmRu(OH2)3][(OTs)2] (16, bottom). 
   
N N
NN
NN
HC Ru
NCCH3
Cl
NCCH3
N N
N
NN
HC Ru
N N
NN
N N CH
PF6
N Cl Cl
 
 
Figure 1.12.  Structures of [TpmRuCl(NCCH3)2][PF6] (17, top) and [Tpm2RuCl][Cl] (18, 
bottom). 
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No reports exist for the synthesis of bis-Tpm ruthenium(II) complexes.  The 
closest structure to a true bis-Tpm ruthenium(II) complex, where all six coordination site 
are occupied by two Tpm ligands, is [Tpm2RuCl][Cl] (18; Figure 1.12), made by 
combining a solution of the ruthenium(III) species TpmRuCl3 and LiCl  in water and a 
solution of Tpm and triethylamine in ethanol and heating to reflux.  As proven by 1H and 
13C NMR spectroscopy, only five of the six pyrazole rings are bound to the metal center.  
Upon removing the chloride with AgClO4 and heating the reaction mixture in acetonitrile 
to reflux to allow for the sixth ring to bind, 1H and 13C NMR spectroscopy showed that 
the metal center exchanged the chloride for an acetonitrile ligand instead of binding the 
sixth nitrogen of the Tpm ligand (19; Scheme 1.2).66 
 
Biological Applications of Ruthenium 
 Although ruthenium is not an essential metal, ruthenium complexes are also of 
biological interest in cancer treatment.  Since the discovery of cisplatin-resistant forms of 
cancer, research has been conducted to discover other transition metal-based 
chemotherapeutic drugs to help combat more aggressive cancer cell lines.67  One of these 
ruthenium drugs is trans-[HIm]-[RuIIICl4(DMSO)(Im)] (NAMI-A,  or new anti-tumor 
metathesis inhibitor-A; 20; Figure 1.13).68  Unlike other ruthenium-based complexes, 
NAMI-A has the ability to eradicate tumor metastases.69  This property may be due to the 
ability of NAMI-A and other Ru(III) complexes with similar structures70 to be 
transported by vacant Fe(II) sites in transferrin and lactoferrin to distant cancer cells.69,71   
 Once these complexes reach target cancer cells, they then interact with either  
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extracellular matrix components72 or some form of cellular receptor68 to enter the cell via 
endocytosis.67 Upon entering the cancerous cell, it is currently believed that the Ru(III) 
center is then reduced to Ru(II) by glutathione.73  Finally, the complex binds to the target 
cell’s DNA via guanine, causing DNA crosslinks and inhibiting the function of 
topoisomerase II.74 
 One study of particular interest is the use of ruthenium(II) arene complexes of the 
type [(η6-arene)Ru(X)(Y)(Z)] (arene = substituted benzene; X, Y, Z = halides,  
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Figure 1.13. Structure of NAMI-A (20). 
 
acetonitrile, isonicotinamide; 21; Figure 1.14), that were synthesized and tested in A2780 
(ovarian) cancer cell growth inhibition assays.  These ruthenium(II) complexes inhibited 
cell growth similarly to that of carboplatin (22; Figure 1.14), and 1H NMR spectroscopy 
indicated that the metal center was strongly bound to the guanine N7 in DNA.76   This 
reinforces the proposal that ruthenium(II) may be a useful mimic for iron(II) in biological 
studies.  It also shows ruthenium complexes of Tp-type ligands may be useful for 
studying metal-ion interactions with DNA. 
 An example of Tp-type ruthenium complexes that are of biological interest is the 
aforementioned [TpmRuCl(NCCH3)2][PF6] (17; Figure 1.12).  This complex was 
originally made as a starting material so that bidentate phosphine ligands could be added.  
The resulting complex was tested in vitro against breast (MCF-7) and cervical (HeLa) 
cancer cell lines.  Complex 17 has shown significant cytotoxicity based on 3-(4,5- 
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Figure 1.14.  Structures of [(η6-arene)Ru(X)(Y)(Z)] (21, left), and carboplatin (22, right). 
 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays,65 a colorimetric 
assay used to measure enzyme activity that can be used the assess the viability and 
proliferation of cells.75  Due to structural similarities of 17 with the arene complex 21, it 
is likely this complex may also bind DNA to exert its anticancer effects. 
 This review shows Tp-type iron(II) and ruthenium(II) complexes have uses in 
catalysis, as biomimetics, and in biological studies.  It also shows that this class of 
complexes has the potential to be used in biologically-relevant studies of DNA.  The 
research presented in Chapter 2 describes the synthesis and characterization of 
tris(pyrazolyl)borate and tris(pyrazolyl)methane complexes of iron(II), with an emphasis 
on electrochemical studies.  Novel iron(II) complexes containing chalcogenates and 
chalcogenones were also synthesized and the studies conducted on these complexes show 
the effects sulfur and selenium have on the electrochemical behavior of iron(II).  These 
studies help us understand how changing the electrochemical behavior of iron(II) affects 
its ability to undergo the Fenton reaction. 
 18
An improved synthetic method for the synthesis of tris(pyrazolyl)borate 
ruthenium(II) complexes as well as the synthesis and characterization of novel 
tris(pyrazolyl)methane complexes of ruthenium(II) are presented in Chapter 3.  The 
improved syntheses of these Tp-type complexes also yields a quick and effective pathway 
for making ruthenium(II) synthons to use in catalysis or as building blocks for subsequent 
synthetic chemistry.  Cyclic voltammetry studies conducted on these species show how 
the coordination of Tp-type ligands alters the electrochemical behavior of ruthenium(II).  
These electrochemical studies show that the coordination of N,N,N-type donors such as 
Tp also affect the redox chemistry of ruthenium.    
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CHAPTER TWO 
SYNTHESIS AND CHARACTERIZATION OF IRON(II) COMPLEXES 
CONTAINING TRIS(PYRAZOLYL) LIGANDS AS WELL AS SULFUR- OR 
SELENIUM-CONTAINING LIGANDS AND THEIR BIOLOGICAL RELEVANCE 
 
Introduction 
In cells, unbound iron(II) is prone to electron transfer reactions that enable it to 
generate hydroxyl radical (OH) in the Fenton reaction (Reaction 1).1  The generated 
hydroxyl radical can cause oxidative stress in cells and damage to DNA.2  Hydroxyl 
radical is an underlying cause of chronic or degenerative diseases and is also a primary 
factor in the aging process.3-10  Therefore it is of great interest to investigate methods to 
prevent hydroxyl radical formation for disease prevention and treatment. 
 
Fe2+  +  H2O2 Fe3+  + .OH  +  OH-             (1)
 
         
Selenium is a required dietary micronutrient for most animals,1,5 and selenium 
compounds have also been reported as vital antioxidants,11,12 protecting and 
strengthening the immune system by preventing radical formation.  World population 
studies show that where the soil is rich in selenium, there are significantly lower levels of 
cancers.13  The Nutritional Prevention of Cancer (NPC) trial found that a regular 
supplement of dietary selenium in humans (200 µg/day) can reduce the occurrence of 
prostate cancer by 63%, colorectal cancer by 58%, carcinoma by 45%, and lung cancer 
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by 48% over a ten year period,14 though a larger study of selenium and vitamin E 
supplementation on prostate cancer, the SELECT trial, found that selenium 
supplementation using yeast enriched with primarily L-selenomethionine (200 µg/day; 
SeMet; Figure 2.1) was not as effective in preventing prostate cancer as once thought.15  
Many population studies have also shown that selenium is a protective nutrient against 
the development of heart and artery disease.16  These findings have led to the 
development of organoselenium drugs, which are less toxic than inorganic selenium and 
appear to be bioavailable.6,7  In Japanese clinical trials, the selenium-containing drug 
ebselen was found effective for treatment of stroke, and 1,2–diselenone-3-pentanoic acid, 
the selenium analog of α-lipoic acid, is a well-studied naturally-occurring antioxidant.17   
Selenium can be found as selenocysteine (SeCys; Figure 2.1) and 
selenomethionine (Figure 2.1) in plants, which naturally replace sulfur in cysteine and 
methionine with selenium absorbed from the soil.18  Selenocysteine is also specifically 
incorporated into the active sites of antioxidant proteins such as glutathione peroxidase 
(GPx),17 thioredoxin reductase,19 and selenoproteins P, W, and R.20   
Selenolates (RSe-) in biological systems coordinate metal ions similarly to 
thiolates (RS-).  Iron thiolate complexes can mimic ferridoxins (Figure 2.2), iron-sulfur 
proteins that are involved in the transfer of electrons in metabolic processes, such as 
those found in the mitochondria of anaerobic bacteria21 and the chloroplasts of plants.22   
Another example of iron thiolate complexes is the family of rubredoxins (Figure 2.2), 
iron-sulfur proteins that are also involved in electron transfer reactions and found 
exclusively in sulfur-processing archaebacteria.23  Selenolate-metal coordination is  
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Figure 2.1.  Structures of sulfur-containing amino acids tested for antioxidant activity. 
 
found in the [NiFeSe] hydrogenases, a group of metalloenzymes also found in sulfur-
processing archaebacteria that catalyze the hydrolysis of hydrogen gas into hydrogen ions 
and electrons.  They are generally heterodimeric, contain three iron–sulfur clusters in 
their small subunit and a nickel-iron-containing active site in their large subunit that 
incorporates a SeCys residue bound to nickel(II).24 
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Figure 2.2.  Structures for the Fe-S clusters in ferredoxin (a) and rubredoxin (b). 
 
The heterocyclic chalcogenone ergothioneine (Figure 2.3), widely found in 
actinobacteria, is an amino acid that is a thiourea derivative of histidine.25 Its selenium 
analog, selenoneine (Figure 2.3), mostly found in fish such as bluefin tuna (430 nmol/g), 
is a major dietary source of selenium for largely fish eating cultures.26  These 
chalcogenones resemble methimazole, a drug currently used in the treatment of 
hyperthyroidism.27  Heterocyclic chalcogenones such as those shown in Figure 2.3 also 
coordinate iron(II) well, since they are σ- and π-donors as well as π-acceptors.  Raper,28 
Akrivos,29 Spicer et al.,30 and Pettinari31 have previously reviewed the coordination 
chemistry of selones and thiones with transition metals and halogens. 
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Figure 2.3.  Structures of ergothioneine and selenoneine (left) and methimazole (right). 
 
Small-molecule sulfur and selenium antioxidants help prevent or minimize 
widespread cellular damage from reactive oxygen species including OH.  Studies by 
Battin et al. have shown using gel electrophoresis DNA damage assays that the sulfur-
containing cellular antioxidants reduced glutathione (GSH) and oxidized glutathione 
(GSSG; Figure 2.1) inhibit iron-mediated DNA damage.  GSH inhibited iron-mediated 
DNA damage (23.0 ± 8.4% inhibition at 10,000 µM) at a concentration well within 
biological concentrations (up to 15,000 µM in the nucleus).  GSSG also inhibited iron-
mediated DNA damage (50.2 ± 4.5% inhibition at 10,000 µM), giving credence as to why 
glutathione is the primary sulfur-containing cellular antioxidant.  In contrast, the sulfur-
containing amino acids cysteine (Cys), cystine (Cys2), and methionine (Met; Figure 2.1) 
do not effectively inhibit iron-mediated DNA damage.  It was determined that metal 
coordination is required for the majority of glutathione antioxidant activity, as determined 
by similar studies conducted with chelated iron (in the form of [Fe(EDTA)]2-) using gel 
electrophoresis.32 
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Selenium concentrations in biological systems are small,33 so it is believed that no 
more than one selenium-containing ligand would typically be involved in biological 
metal coordination.  Battin et al. also used DNA damage assays to study the ability of 
selenium-containing compounds found in biological systems to inhibit iron-mediated 
DNA damage.  Of the 12 selenium compounds studied, only methyl-selenocysteine 
(MeSeCys; Figure 2.4; IC50 of 378.4 ± 0.1 µM) and selenocystamine (SeCysta; Figure 
2.4; IC50 of 121.4 ± 0.3 µM) inhibited iron-mediated DNA damage, although these 
concentrations are much higher than biological selenium concentrations.  It was 
determined, as for the previously tested sulfur-containing compounds, that iron 
coordination is required for the majority of this antioxidant activity.34 
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Figure 2.4.  Structures of selenium-containing amino acids tested for antioxidant activity. 
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Based on these data, synthesis and electrochemical study of biologically-relevant 
Tp-type iron(II) complexes (Figure 2.5) containing chalcogenates and chalcogenone 
ligands may help understand how changing the electrochemical behavior of iron(II) 
affects its ability to undergo the Fenton reaction.  In the attempts to synthesize these 
complexes, two different methods are employed.  One method entailed the chelation of 
iron(II) with Tp-type ligands to form Tp-type iron(II) complexes with labile solvato 
ligands, such as acetonitrile.  Labile solvato ligands were used so that they can be 
replaced with sulfur- or selenium-containing ligands in subsequent steps.  This reaction 
was followed by addition of the chalcogenate or chalcogenone ligands.  The second 
method involved initial coordination of the chalcogenate or chalcogenone ligands to form 
iron(II)-sulfur and -selenium complexes, followed by chelation of the Tp-type ligand. 
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Figure 2.5.  Target iron(II) complexes. 
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Results and Discussion 
Synthesis of Tp-type iron(II) tris(acetonitrile) complexes.  
[Tp*Fe(NCCH3)3][BPh4] (1) was synthesized by slow cannula addition of the potassium 
salt of Tp* (Tp, R = Me) in acetonitrile to iron(II) triflate in acetonitrile.  Immediately, a 
light pink solution formed and potassium triflate (KOTf) precipitated as a white solid.  
After separating the KOTf by cannula filtration, NaBPh4 was added to the solution to 
perform a counteranion exchange, and the mixture was stirred overnight to yield a red 
solution.  The volume of the solvent was reduced, and diethyl ether was added to 
precipitate a white solid (Figure 2.6).  The 1H NMR spectrum for 1 is quite similar to that 
reported for its Fe-Tpm* analog.35  The BH proton appears as a broad singlet at δ -12, the 
two methyl groups at δ 39 and δ 14, and the 4-H of the pyrazole appears at δ 58.  A sharp 
peak at δ -79 in 19F{1H} NMR indicates the presence of uncoordinated triflate ion. 
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Figure 2.6.  Synthesis of [Tp*Fe(NCCH3)3][BPh4] (1); yield 65%. 
 
The IR spectrum of the free Tp* ligand shows a B-H stretching vibration at 2470 
cm-1, and the bound acetonitrile on iron(II) triflate of the form Fe(OTf)2(NCCH3)2 has a 
nitrile stretching vibration at 2292 cm-1.  Upon Tp* coordination to iron(II) triflate, the B-
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H stretch shifts to 2924 cm-1, a significantly higher energy relative to the unbound ligand, 
indicative of strong donor bonding to iron.  The nitrile stretch from the iron-bound 
acetonitrile ligands shifts to 2319 cm-1, a higher energy, indicating stronger donor bonds 
between iron and acetonitrile upon addition of both Tp* and an acetonitrile solvato 
ligand. 
[Tpm*Fe(NCCH3)3][(BPh4)2] (2) was synthesized similarly to a reported 
procedure  (Tpm* = Tpm, R = Me;35 Figure 2.7).  The 1H NMR spectrum shows a broad 
resonance at δ -42.2, characteristic of the apical CH proton.  Broad resonances at δ 54 (4-
H on the pyrazole ring), 35 (3-methyl), and 12.7 (5-methyl) are due to Tpm* coordination 
to the metal ion.  The 19F{1H} NMR spectra shows a singlet at -79 ppm, indicating the 
presence of uncoordinated triflate anion. 
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Figure 2.7.  Synthesis of [Tpm*Fe(NCCH3)3][(BPh4)2] (2), yield 43%. 
 
 Attempts to coordinate sulfur- and selenium-containing ligands using sodium 
phenylthiolate (NaSPh), sodium phenylselenolate (NaSePh), 1,3-dimethylimidazole-2-
thione (DImT), and 1,3-dimethylimidazole-2-selone (DImSe; Figure 2.8) to 
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tris(acetonitrile) complexes 1 and 2 afforded products that could not be separated from 
the reaction mixture, as determined from paramagnetic 1H NMR spectra.  
Synthesis of iron(II) sulfur and selenium compounds.  Since sulfur- and selenium-
containing ligands do not provide clean products with Tp-type iron(II) complexes,  
Fe(EPh)42- complexes (E = S, Se; Figure 2.9) were synthesized to attempt to synthesize 
the target iron(II) complexes.  This approach differs as it involves coordinating the 
chalcogen to the metal before addition of the Tp-type ligand.  
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Figure 2.8.  Sulfur- and selenium-containing compounds used in this work. 
 
The iron(II) selenolate complex (3) was prepared as previously reported,36 but 
was modified to prepare the iron(II) thiolate complex (4).  Addition of hydrated iron(II) 
chloride to sodium phenylthiolate yielded a dark purple solution and purple crystals of 4 
upon cooling overnight.  Comparison of the paramagnetic 1H NMR spectra of 3 and 4 to 
the reported values for the phenylselenolate complex suggest that the protons of the 
ortho, meta, and para positions from the phenylselenolate ligands are reversed from what 
was reported.  Specifically, the resonances for the ortho and para protons have a positive 
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chemical shift (δ 18 and 16, respectively, compared to δ -16 and -18 reported) and the 
meta proton has a negative chemical shift (δ -16.5 compared to the reported δ 16). 
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Figure 2.9. Preparation of [Fe(SePh)4][(PPh4)2]36 (3) and [Fe(SPh)4][(PPh4)2] (4). 
 
To compare iron(II) complexes with different sulfur- and selenium-containing 
ligands, [Fe(DImE)2][(OTf)2] compounds were synthesized, where E is again sulfur (5) 
or selenium (6; Figure 2.10).  Paramagnetic 1H NMR spectra of 5 shows a downfield shift 
from δ 3.5 (N-Me) and δ 6 (olefinic) for the free thione to δ 11 and δ 10, respectively, for 
the bound thione ligand.  The spectra also show two resonances each for the methyl and 
olefinic protons, suggesting that the protons of the imidazole ligands have different 
environments.  This same phenomenon is seen in the 1H NMR spectrum of 6. 
The IR spectrum of the free thione shows a C=S stretching vibration at 1181 cm-1, 
whereas the free selone has a C=Se stretching vibration at ~1148 cm-1, consistent with 
previous reports for DImT, 1,1'-methylenebis(1,3-dihydro-3-methyl-2H-imidazole-2- 
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Figure 2.10.  Synthesis of [Fe(DImT)2][(OTf)2] (5) and [Fe(DImSe)2][(OTf)2] (6). 
 
thione) (Mbit), and 1,1'-methylene-bis(1,3-dihydro-3-methyl-2H-imidazole-2-selone) 
(Mbis).37-39  Upon DImT coordination to iron(II) triflate, the C=S stretch shifts to 1174 
cm-1, a lower energy relative to the unbound ligand indicative of weak iron backbonding 
to the thione ligand.  Coordination of DImSe to iron(II) triflate results in a shift of the 
C=Se stretch to 1155 cm-1, a slightly higher energy, indicating that iron backbonding 
interactions with this ligand are not significant.  A similar difference in vibrational 
energies is seen for DImT and DImSe binding to copper(I).40 
 Attempts at coordinating Tp* and Tpm* to both types of sulfur- and selenium-
containing complexes yield a variety of results.  Paramagnetic 1H NMR spectra indicate 
that addition of Tp* and Tpm* to complexes 3 – 6 yielded results ranging from no 
reaction to ligand disproportionation upon addition of TpR ligands (Figure 2.11).    
 A comparison of the electrochemistry of iron(II) complexes.  Cyclic voltammetry 
was performed on the new iron(II) complexes to understand how coordination of both  
 36
 
Figure 2.11.  Results of adding Tp-type ligands to the synthesized iron(II) sulfur- and 
selenium-containing complexes.  All reactions were performed in acetonitrile. 
 
Tp-type ligands and sulfur- and selenium-containing ligands to iron(II) affects its redox 
chemistry.  Changing the redox chemistry may affect the ability of iron(II) to generate 
hydroxyl radical in the Fenton reaction.  
Upon comparing the measured Fe2+/Fe3+ potentials (Table 2.1) of the Tp-
containing iron complexes with the sulfur- and selenium-containing iron complexes, it is 
clear that addition of a single Tp-type ligand to iron(II) triflate generally results in more 
positive Fe2+/3+ potentials.  These potentials indicate that iron(II) is less stable relative to 
iron(III).  On the other hand, the addition of sulfur- and selenium-containing ligands to 
iron(II) triflate yields negative potentials, indicating that sulfur and selenium coordination 
stabilizes iron(II) relative to iron(III).   
The potentials in Table 2.1 show that the addition of multiple Tp* ligands to iron 
result in lower Fe2+/3+ potentials.  For example, the bis Tp-type analog, Tp*2Fe, has a 
more negative reversible Fe2+/3+ potential of 0.241 V vs. normalized hydrogen electrode    
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Table 2.1: Fe2+/3+ potentials for target complexes (E vs. NHE). 
Complex Epa (V) Epc (V) E½, Fe2+/3+ (V) Ref. 
Fe(OTf)2(NCCH3)2 0.633 0.913 0.771 This work 
Tp*2Fe 0.189 0.294 0.241 41 
[Tpm*2Fe][(OTf)2] 0.916 1.02 0.968 41 
[Tp*Fe(NCCH3)3][BPh4] (1) 0.698 0.850 0.776 41 
[Tpm*Fe(NCCH3)3][(BPh4)2] (2) 0.879 1.04 0.761 41 
[Fe(SPh)4][(PPh4)2] (3) -0.650 -0.796 -0.723 This work 
[Fe(SePh)4][(PPh4)2] (4) -1.07 -0.942 -1.01 This work 
[Fe(DImT)2][(OTf)2] (5) -1.31 -0.176 -0.547 This work 
[Fe(DImSe)2][(OTf)2] (6) -0.401 -0.047 -0.047 This work 
   
(NHE) than both the mono Tp-type analog 1 (0.776 V) and iron(II) triflate (0.771 V).  
The potentials show that the coordination of multiple Tp* ligands stabilizes iron(III) 
relative to iron(II) better than does a single Tp* ligand due to the negative charge of the 
Tp* ligand.   
Conversely, the potentials in Table 2.1 show that addition of multiple neutral 
Tpm* ligands to iron yields a more positive potential than having one neutral Tpm* 
ligand coordinated to iron(II).  The Tpm analog, [Tpm*2Fe][(OTf)2], has a more positive 
reversible Fe2+/3+ potential of 0.968 V vs. NHE than that of the mono Tpm analog 2 
(0.761 V).  Also note that 2 has a slightly lower potential than iron(II) triflate (0.771 V).  
This trend can be explained due to the presence of the acetonitrile solvato ligands.  Recall 
that the IR spectrum of iron(II) triflate of the form Fe(OTf)2(NCCH3)2 has a nitrile 
stretching vibration for its bound acetonitriles at 2292 cm-1.  The nitrile stretching 
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vibration for 2 is shifted to a lower energy, 2283 cm-1, upon addition of both Tpm* and 
an additional acetonitrile.  The coordinated nitrogens of acetonitrile have the ability to σ-
donate and π-accept when bound to a metal center, resulting in backbonding of its d 
orbitals to the empty π* orbital of the acetonitrile nitrogens, which is indicated by the 
lower vibrational energy.  Thus, since [Tpm*Fe(NCCH3)3][(BPh4)2] (2) gains one solvato 
ligand, it yields the slightly lower potential regardless of Tpm* coordination; the bis 
analog has no solvato ligands from which it can backbond compared to 2, thus the higher 
potential.  Thus the addition of multiple neutral Tpm* ligands better stabilizes iron(II) 
relative to iron(III) than does adding one Tpm* ligand.    
However, the previous trend only holds true if more than one charged N,N,N-type 
donor is added to the metal center.  [Tp*Fe(NCCH3)3][BPh4] (1; 0.776 V) has a 
reversible Fe2+/3+ potential that only differs by 15 mV as compared to complex 2 (0.761 
V).    But when more than one trinitrogen donor is added, the difference in potential 
widens greatly between Tp*2Fe and [Tpm*2Fe][(OTf)2] (727 mV).  The potentials again 
show that the addition of charged species results in the stabilization of iron(II) over 
iron(III).  The potentials also show that the charge of the trinitrogen donor has minimal 
effect on potential when only one ligand is coordinated to the metal center. 
Comparing the Fe2+/3+ potentials for the iron chalcogenate complexes, it can be 
seen that selenolate coordination of 4 (-1.01 V) negatively shifts the potential of the 
iron(II) compared to its thiolate analog, 3 (-0.723 V).  This is because the selenolate is a 
softer base than the thiolate, meaning that the selenolate has more polarizable valence 
electrons than the thiolate.  Although iron(II) is a borderline acid, the softer selenolate 
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will donate its pair of electrons through σ-donation more effectively than the thiolate, 
more effectively stabilizing iron(II) over iron(III).    
In contrast, comparing the electrochemical potentials of complexes 5 and 6 show 
that the thione (-0.547 V) has a more negative potential than the selone (-0.047 V).  The 
results can be explained using previously-discussed IR data for 5 and 6.  Recall that the 
C=S stretch for 5 shifts to a lower energy relative to the unbound thione ligand, whereas 
the C=Se for 6 shifts to a slightly higher energy compared to unbound selone.  Thus, 
backbonding to the thione ligand is more significant than to the selone ligand, indicating 
that the electrons from the thione ligand are not as readily donated to the iron center than 
with the selone ligand.  These data show that both the thione and selone stabilize the 
iron(II) metal center relative to iron(III), but the selone is more effective at stabilizing the 
iron(II) center than the thione.   
Biological implications of this work.  The biological Fenton reaction occurs only 
over a specific electrochemical range (-0.324 V to 0.460 V).42  To illustrate the biological 
implications of the potentials in Table 2.1, Figure 2.13 shows the potentials of the iron 
complexes relative to the electrochemical window in which the Fenton reaction can 
occur.  Previous reports have shown that complexation of iron(II) alters its 
electrochemical properties compared to iron(II).18  Based on the electrochemical 
potentials for the iron(II) complexes, chelation of either the DNA mimic Tp-type ligands 
or sulfur and selenium may inhibit the Fenton reaction.  Tp-type coordination to iron(II) 
may stabilize iron(II) to H2O2 oxidation, whereas sulfur and selenium coordination may 
stabilize iron(III) to NADH reduction, preventing iron redox cycling.  These findings are 
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consistent with the findings of Battin et al., where coordination of selected sulfur- and 
selenium-containing compounds is a mechanism for preventing iron-mediated DNA 
damage.32,34  
 
 
 
 
Figure 2.12.  Depiction of where the potentials of iron(II) complexes lie in relation to the 
electrochemical window for the biological Fenton reaction.  
 
 Based on the findings presented in this chapter, it can be concluded that 
coordination of ligands to iron can significantly alter its electrochemical behavior.  The 
ability to stabilize either oxidation state of iron (+2 or +3) is important not only to 
biological systems, but could also be used to tune the reactivity of iron complexes for use 
in catalysis.   
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Experimental Methods 
General air-sensitive techniques under argon were used to synthesize the 
complexes unless otherwise stated.  1H and 19F{1H} NMR spectra were obtained using a 
Bruker-AVANCE NMR spectrometer at 300 MHz.  1H NMR chemical shifts are reported 
in δ relative to tetramethylsilane (TMS) and referenced to solvent. 19F{1H} NMR spectra 
were externally referenced to CCl3F (δ 0).43  Infrared spectra were obtained using Nujol 
mulls on KBr salt plates with a Magna 550 IR spectrometer.  Abbreviations used in the 
description of vibrational data are as follows: vs, very strong; s, strong; m, medium; w, 
weak; b, broad.  Electrospray ionization mass spectrometry (ESI-MS) was conducted 
using a QSTAR XL Hybrid MS/MS System from Applied Biosystems via direct injection 
of sample (0.05 mL/min flow rate) into a Turbo Ionspray ionization source.  Samples 
were run under positive mode in methanol, with ionspray voltage of 5500 V, and in TOF 
scan mode.  Peak envelopes match theoretical calculations for their ions.  Elemental 
analyses were performed in-house on a Perkin Elmer 2400 Series II CHNS/O Elemental 
analyzer.  
Methyl iodide, potassium borohydride, 3,5-dimethylpyrazole, precipitated sulfur, 
sulfur powder, and tetra-n-butylammonium bromide were purchased from Alfa Aesar; 
sodium hydride, diethyl ether, hydrated iron(II) chloride, diphenyl diselenide, and iron 
powder were purchased from Fisher/Acros; methanol, and acetonitrile were purchased 
from Mallinkrodt; chloroform and sodium sulfate were purchased from BDH; sodium 
tetraphenylborate was purchased from Lancaster; dry methanol was purchased from 
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Burdick; and diphenyl disulfide, 1-methylimidazole, and tetraphenylphosphonium 
chloride were purchased from TCI.   
Iron(II) triflate,44 KTp*,45 Tpm*,46 sodium phenylselenolate (NaSePh),47,48 
sodium phenylthiolate (NaSPh),47,48 1,3-dimethylimidazole-2-thione,49 1,3-
dimethylimidazole-2-selone,49 and [Fe(SePh)4][(PPh4)2]36 were synthesized using 
reported procedures.  [Tpm*Fe(NCCH3)3][(BPh4)2] was synthesized according to the 
procedure reported for synthesizing [(Tpm*)Fe(NCCH3)3][(BF4)2].35 
Synthesis of [Tp*Fe(NCCH3)3][BPh4], 3.  The potassium salt of Tp* (1) (0.168 g, 
0.5 mmol) dissolved in acetonitrile (10 mL) was added dropwise using a cannula to a 
solution of Fe(OTf)2 . 2 CH3CN (0.5 mmol, 0.22 g) in acetonitrile (10 mL), and the 
solution was stirred for 30 min.  A white precipitate formed and the solution turned 
gradually to a pale pinkish-red color.  The white solid was separated using cannula 
filtration, and a solution of NaBPh4 (0.171 g, 0.5 mmol) dissolved in acetonitrile (15 mL) 
was added and stirred overnight.  The solution was concentrated by reducing the volume 
of the solvent to 2 mL, and a dull white solid precipitated.  Ether (10 mL) was added to 
facilitate precipitation, and the light pink solid was separated by cannula filtration, 
washed with ether (2 × 5 mL), and vacuum dried.  Total yield: 0.258 g, 65%.  1H NMR 
(acetone-d6): δ 59 (3H, 4-H(pz)), 39 (9H, -Me), 14 (9H, -Me), 6.95 (t, -Ph), 6.75 (t, -Ph).  
IR (cm-1): 486 w, 596 w, 652 w, 721 m, 847 w, 1030 w, 1152 w, 1304 w, 1543 w, 1578 
w, 2265 w, 2326 w, 2360 w, 2665 w, 2730 w.   
Synthesis of [Fe(SPh)4][(PPh4)2], 5.  Hydrated iron(II) chloride (1.0 g, 4.27 
mmol) in acetonitrile (50 mL) was added dropwise to a stirring solution of sodium 
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phenylthiolate (2.31 g, 17.5 mmol) in acetonitrile (30 mL) and the resulting brown 
solution was then heated to 60°C for 30 min.  Tetraphosphonium chloride (3.36 g, 8.96 
mmol) was added and heated for an additional 15 min and filtered.  Diethyl ether (40 mL) 
was added to the solution to facilitate crystallization, and the solution was stored 
overnight at -20°C to afford purplish-brown crystals.  Total yield: 4.4 g, 88%.  1H NMR 
(DMSO-d6): δ -24 (s, 8H, SPh m-H), 7.37 (s, 8H, PPh o-H), 7.79 (s, 4H, PPh p-H), 7.95 
(s, 8H, PPh m-H), 20.5 (s, 8H, SPh p-H), 21.5 (s, 4H, SPh o-H). 
Synthesis of Fe(DImT)2(OTf)2, 7.  A mixture of 1,3-dimethylimidazole-2-thione 
(0.151 g, 1.2 mmol) and iron(II) triflate (0.25 g, 0.6 mmol) was dissolved in methanol (15 
mL) and stirred for 12 h, resulting in a yellow solution.  The solvent was removed in 
vacuo, and the green solid was extracted with dichloromethane (2 × 7 mL) and filtered.  
The filtrate was dried in vacuo to yield a bluish-green solid.  Total yield: 0.269 g, 74%.  
1H NMR (CD3CN): δ 15.2 (2H, Im-H), 10 (2H, Im-H), 6.2 (3H, Im-Me), 5.9 (6H, Im-
Me).  19F{1H} NMR (CD3CN): δ -74.5 (s).  IR (cm-1): 635 s, 678 w, 757 w, 801 w, 1035 
vs, 1091 w, 1174 vs, 1260 vs, 1561 m, 1655 w, 2345 w, 2373 w, 3126 m, 3152 m, 3484 
b.  Mass spectrum (ESI-MS): m/z 460.9 [Fe(DImT)2(OTf)]+, 318.9 [Fe(DImT)2]+.  Anal. 
Calc. for FeC12H16S4F6O6N4: C, 19.66; N, 10.49; H, 2.62.  Found: C, 18.77; N, 10.91; H, 
3.01.   
Synthesis of Fe(DImSe)2(OTf)2, 8.  A mixture of 1,3-dimethylimidazole-2-selone 
(0.208 g, 1.2 mmol) and iron(II) triflate (0.25 g, 0.6 mmol) was dissolved in methanol (20 
mL) and stirred for 12 h, resulting in an orange solution.  The solvent was removed in 
vacuo, extracted with dichloromethane (2 X 7 mL), and filtered.  The filtrate was dried in 
 44
vacuo to yield a dark red solid.  Total yield: 0.193 g, 46%.  1H NMR (CD3CN): δ 16.3 
(2H, Im-H), 11.2 (2H, Im-H), 6.2 (3H, Im-Me), 5.9 (6H, Im-Me).  19F{1H} NMR 
(CD3CN): δ -75 (s).  IR (cm-1): 638 s, 740 w, 798 m, 1029 vs, 1094 m, 1155 s, 1259 vs, 
1561 m, 1655 w, 2345 w, 2373 w, 3108 m, 3142 m, 3449 b.  Calc. for 
FeC12H16S2F6O6N4Se2: C, 17.04; N, 9.09; H, 2.27.  Found: C, 18.07; N, 10.21; H, 2.31.    
Electrochemical studies of synthesized iron(II) complexes.  Cyclic voltammetry 
(CV) experiments were carried out using CHI Electrochemical analyzer and employed a 
three-electrode cell consisting of glassy carbon working electrode, a Ag/AgCl reference 
electrode, and a platinum wire auxiliary electrode.  The glassy carbon electrode was 
polished with alumina prior to each trial.  CV experiments were conducted in acetonitrile 
containing 0.1 mM complex and 0.1 M tetra-n-butyl ammonium hexaflurophosphate 
(TBAPF6) at a scan speed of 0.1 V/s from -1.25 V to 1.25 V.  Solutions were 
deoxygenated with dry nitrogen gas and maintained under a blanket of nitrogen during 
measurements, and voltammograms were referenced to the ferrocene/ferricenium couple 
(Fc+/0) at 0.46 V.50  Formal potentials were evaluated as E½ = (Epa+Epc)/2, where Epa and 
Epc are anodic and cathodic peak potentials.   
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CHAPTER THREE 
 
SYNTHESIS AND CHARACTERIZATION OF RUTHENIUM(II) COMPLEXES 
CONTAINING TRIS(PYRAZOLYL) BORATE AND –METHANE LIGANDS  
 
Introduction 
Although ruthenium is not a biologically essential metal like iron, ruthenium 
complexes are of biological interest.  They have been shown to aid in the treatment of the 
rejection of cadaver skin grafting,1 autoimmune deficiencies,2 and the kinetic study of 
glutathione oxidation.3  It is also of interest in cancer treatment; the discovery of 
cisplatin-resistant forms of cancer has lead researchers to investigate transition metal-
based chemotherapeutic drugs in addition to platinum drugs that could interact with 
DNA, such as the ruthenium-containing compound NAMI-A, to help combat aggressive 
cancer cell lines.4,5  The advantage to using ruthenium in this work is that it is in the same 
group as iron, but it is a soft, inert metal unlike borderline iron(II).  Ruthenium(II) is also 
diamagnetic, unlike its paramagnetic iron(II) cousin, making NMR data evaluation more 
tractable.  These properties make ruthenium(II) ideal for coordination studies related to 
iron(II) and can also be a useful substitute for iron(II) in biological studies of DNA 
binding.   
Ruthenium(II) arene complexes of the type [(η6-arene)Ru(X)(Y)(Z)] (arene = 
substituted benzene, X, Y, Z = halides, acetonitrile, isonicotinamide; Figure 3.1) exhibit a 
similar inhibition of cell growth to that of carboplatin, an analog of cisplatin  (Figure 3.1), 
and 1H NMR spectroscopy indicated that the metal center was strongly bound to the 
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guanine N7 in DNA.4  The use of capping N,N,N-type ligands, such as the Tp-type 
ligands, in ruthenium-based complexes may allow the study of how ruthenium(II) 
interacts with DNA.  Tp-type ruthenium complexes, such as [TpmRuCl(NCCH3)2][PF6], 
have shown significant cytotoxicity against breast (MCF-7) and cervical (HeLa) cancer 
cell lines.6 
  
Ru
X
Y
Z
R
Pt
NH3H3N
O O
OO
 
Figure 3.1.  Structures of [(η6-arene)Ru(X)(Y)(Z)] (left), and carboplatin (right). 
 
Much work is also being conducted to develop ruthenium catalysts that improve 
reaction efficiency in an effort to advance the principles of green chemistry.  Various 
coordination complexes of ruthenium exhibit industrially-significant catalytic properties.  
For example, the complex RuH2(PPh3)4 (Figure 3.2) catalyzes the conversion of nitriles 
to amides,7 esterification using alcohols and nitriles,8 and the polymerization of nylon-
6,6,7 among other reactions.  The most notable ruthenium-based catalysts, the Grubbs 
catalysts (Figure 3.2), enable various olefinic metatheses such as in ring-opening 
polymerization and ring closures.9 By using these catalytic synthetic methods, 
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improvements can be made in various organic reactions’ atom efficiencies and their 
selectivity. 
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Figure 3.2.  Structures of RuH2(PPh3)4 (left), Grubbs catalyst, 1st generation (Cy = 
cyclohexane; middle), and Grubbs catalyst, 2nd generation (right). 
 
The primary ruthenium source for organometallic and coordination chemistry is 
ruthenium(III) chloride hydrate, used to synthesize the commonly-used synthons 
RuCl2(PPh3)310 and polymeric [RuCl2(COD)]x11 (COD = 1,5-cyclooctadiene; Figure 3.3).  
Use of RuCl2(PPh3)3 and [RuCl2(COD)]x in subsequent reactions results in complexes 
that contain triphenylphosphine or COD ligands, substituents that are undesirable in 
further substitution reactions due to their tendency to crowd available coordination sites 
because of their steric bulk.  Another reported ruthenium starting material, 
[Ru(NCCH3)6][ZnCl4]12 does not have the issues with sterically-bulky ligands in its 
coordination sphere, but is an undesirable material to use in subsequent coordination 
reactions, since competitive binding of the coordinating ligands may occur between the 
ruthenium cation and the zincate anion.   
The family of tris(acetonitrile) tris(pyrazolyl) ruthenium(II) complexes are of 
great interest, since these would make excellent synthons for a variety of ruthenium  
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Figure 3.3.  Structures of RuCl2(PPh3)3 (left) and [RuCl2(COD)]x (right). 
 
chemistry.  However, there are few reports of the synthesis of these complexes.  
Synthesis of Tp-type ruthenium(II) complexes of the formula [TpRRu(NCCH3)3][X] (R = 
H, Me, iPr; X = PF6-, OTf-) requires multiple steps and the use of many chemicals, but 
synthesis of [TpRu(NCCH3)3][PF6]13 (Scheme 3.1), [Tp*Ru(NCCH3)3][OTf]14 (Scheme 
3.2), and [TpiPrRu(NCCH3)3][OTf]15 (Scheme 3.2) have all been reported.  Interestingly, 
there are no reports of syntheses of analogous Tpm-type ruthenium(II) complexes of the 
formula [TpmRRu(NCCH3)3][(X)2] (R = H, Me, iPr, Ph; X = PF6-, OTf-).  Closely related 
Tpm-type ruthenium(II) complexes that have been reported also require many steps to 
synthesize, including [TpmRuCl(NCCH3)2][PF6]6 (Scheme 3.3) and 
[TpmRu(OH2)3][(OTs)2]16 (Scheme 3.3).  This chapter presents a new method to 
synthesize hexakis(acetonitrile) ruthenium(II) complexes containing uncoordinated 
nonmetallic counteranions and tris(acetonitrile) tris(pyrazolyl)borato ruthenium(II) 
complexes with reduced reaction times, and a general method to synthesize novel 
tris(acetonitrile) tris(pyrazolyl)methano ruthenium(II) complexes (Figure 3.4). 
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Scheme 3.2 
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Scheme 3.3 
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Figure 3.4. Structures of target ruthenium(II) complexes discussed in this chapter. 
 
Results and Discussion 
 Synthesis and characterization of hexakis(acetonitrile) ruthenium(II) starting 
materials.   The only reported syntheses of hexakis(acetonitrile) ruthenium(II) starting 
materials are those of [Ru(NCCH3)6][(BF4)2] (1),20  reported in 1974, and 
[Ru(NCCH3)6][ZnCl4],12 reported in 2001.  Surprisingly, these complexes have not been 
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utilized as starting materials for additional ruthenium chemistry; this is most likely 
because 1 requires many steps to synthesize (Scheme 3.4) and the ruthenium(II) zincate 
species contains a counteranion capable of ligand coordination that would cause 
undesired competitive binding.  Reported characterization was limited to IR and 1H NMR 
spectroscopy, as well as elemental analysis, for both reported [Ru(NCCH3)6]2+ species. 
 
Scheme 3.4 
RuCl3 . 3 H2O
NBD
EtOH, reflux 24 h
Ru
Cl Cl
n
Ru
Mg
Cl
Et2O, 12 h
2
1. CH2Cl2
2. CH3CN
   3. 2 HBF4,
100oC, 5 min
Ru
H3CCN
H3CCN NCCH3
H3CCN
CH3CN
reflux, 24 h
2 BF4
Ru
H3CCN NCCH3
NCCH3
H3CCN NCCH3
H3CCN
2 BF4
 
 
Using an improved synthetic method, two [Ru(NCCH3)6][(X)2] complexes (X = 
BF4-; 1 and X = OTf-; 2) were prepared similarly to that of [Ru(NCCH3)6][ZnCl4],12 but 
with a counteranion exchange step (with NaBF4 or NaOTf) after reduction of the 
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ruthenium to remove the zincate anion.  After workup, a light yellow solid is obtained 
(Figure 3.5).  Using this procedure, 1 and 2 were obtained in yields of 66% and 60%, 
respectively, as compared to 80% for the previous preparation of 1 and 36% for the 
zincate species.  Overall, synthesis of 1 using this method is significantly shorter with 
three fewer steps, and results in a product without a counterion capable of ligand 
coordination (Table 3.1).    
 
2 RuCl3 . 3 H2O
Zn
CH3CN, reflux 1 h
[Ru(NCCH3)6][ZnCl4]
                +
      RuCl2(NCCH3)4
4 NaX
reflux 16 h
2 [Ru(NCCH3)6][(X)2] 
  +  4 NaCl  +  ZnCl2
X = BF4- , OTf-
 
Figure 3.5.  Synthesis of ruthenium(II) starting materials. 
 
Table 3.1.  List of synthetic parameters for selected ruthenium(II) acetonitrile complexes. 
 
Complex Steps 
Reaction 
Time 
 
 
% Yield 
 
Ref 
[Ru(NCCH3)6][(BF4)2] 4 60 h 80 20 
[Ru(NCCH3)6][ZnCl4] 1 2 h 36 12 
[Ru(NCCH3)6][(BF4)2] (1) 1 13 h 66 This work 
[TpRu(NCCH3)3][PF6] 3 33 h 70 13 
[TpRu(NCCH3)3][BF4] (3) 1 1 h 56 This work 
[Tp*Ru(NCCH3)3][OTf] 7 46 h 72 14 
[Tp*Ru(NCCH3)3][OTf] (4) 1 30 min 65 This work 
[TpPhRu(NCCH3)3][OTf] (5) 1 15 min 53 This work 
[Tpm*Ru(NCCH3)3][(BF4)2] (6) 1 12 h 72 This work 
[TpmPhRu(NCCH3)3][(OTf)2] (7) 1 8 h 22 This work 
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Characterization of 1 and 2 matches reported values for 1H NMR and IR 
spectra.12,20  In both cases, the bound acetonitrile shifts downfield in the 1H NMR 
spectrum to δ 2.68 and 2.52, respectively, compared to δ 2.10 for unbound acetonitrile.  
The IR spectra for both 1 and 2 show nitrile stretching frequencies of 2326 cm-1 and 2373 
cm-1, consistent with reported values of 2300 cm-1 and 2325 cm-1 for nitrile stretches of 1 
and the ruthenium(II) zincate species.  This shift to higher energies upon ruthenium(II) 
binding relative to free acetonitrile (2250 cm-1) indicates an increased nitrile bond 
strength due to donor bond formation upon ruthenium(II) complexation. 
Single crystal X-ray diffraction data was collected for [Ru(NCCH3)6][(BF4)2] (1), 
which crystallized as colorless cubes by slow vapor diffusion of diethyl ether into an 
acetonitrile solution, and compared to the reported structure of [Ru(NCCH3)6][ZnCl4].12  
Selected bond lengths for 1 are summarized in Table 3.2, and its structure is shown in 
Figure 3.6.  1 crystallized with a unit cell in the monoclinic P21/c with unit cell 
dimensions of a = 8.0993(16), b = 8.1969(16), c = 15.877(3) Å, α = 90.00, β = 92.78(3), γ 
= 90.00°, whereas the zincate species crystallized with a unit cell in the trigonal R-3 
space group with larger unit cell dimensions than 1 (a = 11.744, b = 11.744, c = 30.932 
Å, α = 90.000, β = 90.000, γ = 120.00°).   Similar average Ru-N bond distances of 
2.03(7) Å were observed for the two [Ru(NCCH3)6]2+ species.  The packing structure of 1 
shows a close contact between F(2) and the H on C(6) (2.50 Å) that is smaller than the 
sum of their van der Waal radii (2.67 Å) and can be seen in the packing diagram viewed 
along the a-axis (Figure 3.7).  No interactions are observed between ions for the 
[Ru(NCCH3)6][ZnCl4] structure.12  With an improved synthetic method for 
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Ru[(NCCH3)6]2+ species 1 and 2, these materials can be used as synthons to synthesize 
tris(acetonitrile) ruthenium(II) complexes with trinitrogen donor ligands. 
 
Table 3.2.  Selected bond lengths [Å] and angles [º] for [Ru(NCCH3)6][(BF4)2] (1).  
_____________________________________________________________  
             
              Ru(1)-N(2)                     2.023(3)  
            Ru(1)-N(3)                     2.024(3)  
            Ru(1)-N(1)                     2.028(3)  
            N(2)-C(5)                       1.133(4)  
            N(3)-C(7)                       1.130(4)  
            N(1)-C(3)                       1.137(4)  
            F(2)-B(1)                        1.395(6)  
            F(3)-B(1)                        1.398(6)  
            F(4)-B(1)                        1.397(5)  
            F(1)-B(1)                        1.390(6)  
            C(7)-C(8)                        1.449(5)  
            C(3)-C(4)                        1.461(5)  
            C(6)-C(5)                        1.451(5)             
            N(2)-Ru(1)-N(3)             90.14(11)  
            N(2)-Ru(1)-N(1)             89.30(11)  
            N(3)-Ru(1)-N(1)             91.79(11)  
            C(5)-N(2)-Ru(1)             175.8(3)  
            C(7)-N(3)-Ru(1)             174.6(3)  
            C(3)-N(1)-Ru(1)             173.4(3)  
            F(1)-B(1)-F(2)                108.2(4)  
            F(1)-B(1)-F(4)                110.8(4)  
            F(2)-B(1)-F(4)                108.6(4)  
            F(1)-B(1)-F(3)                109.9(4)  
            F(2)-B(1)-F(3)                109.7(4)  
            F(4)-B(1)-F(3)                109.5(4)  
            N(3)-C(7)-C(8)               179.4(4)  
            N(1)-C(3)-C(4)               178.0(4)  
            N(2)-C(5)-C(6)               178.7(4)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms: -x+2,-y,-z+2      
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Figure 3.6.  Crystal structure diagram of [Ru(NCCH3)6][(BF4)2].  Density surfaces show 
50% probability ellipsoids.  
 
 Synthesis and characterization of the tris(pyrazolyl)borato-type 
tris(acetonitrile) ruthenium(II) complexes.  The only reported complexes of the formula 
[TpRRu(NCCH3)3]+ are [TpRu(NCCH3)3][PF6],13 [Tp*Ru(NCCH3)3][OTf],14 and 
[TpiPrRu(NCCH3)3][OTf].15  These complexes have not been utilized as starting materials 
for other ruthenium chemistry, likely because of the time and number of steps required to 
synthesize the materials (Schemes 3.1 and 3.2).  Using [Ru(NCCH3)6]2+ complexes 1 and 
2 as starting materials, complexes of the formula    
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Figure 3.7. Packing diagram of [Ru(NCCH3)6][(BF4)2] viewed along the a-axis of the 
unit cell. 
 
[TpRRu(NCCH3)3][X] (R = H, Me, Ph; X = BF4, OTf) were synthesized according to a 
new procedure (Figure 3.8; Table 3.1). 
The first complexes made using the improved procedure, [TpRu(NCCH3)3][BF4] 
(3) and [Tp*Ru(NCCH3)3][OTf] (4), have yields of 56% and 65%, respectively as 
compared to reported yields of 70% and 72%, respectively.13,14  However, the improved 
synthetic method significantly cuts the number of steps (by two for 3, six for 4) and the 
amount of time to obtain a final product (by 35 h and 44 h for 3 and 4, respectively) with 
only an average yield reduction of 15%.  Previous reports have characterized 3 using IR, 
1H, and 13C{1H} NMR spectroscopies as well as elemental analysis,13 whereas 4 was  
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Figure 3.8.  Synthesis of [TpRRu(NCCH3)3][X]. 
 
previously characterized using 1H NMR spectroscopy and elemental analysis.14  
Characterization of 3 and 4 match reported values for 1H NMR spectra, and the 19F{1H} 
NMR spectra shows a single resonance for 3 and 4 (δ -148.3 and -77.8, respectively), 
indicating that the counteranion is not coordinated to the ruthenium center.  The IR 
spectra of both 3 and 4 showed a vibrational energy for the bound acetonitrile ligands at 
2344 cm-1 and 2472 cm-1, respectively, compared to 2326 and 2373 cm-1 for 
[Ru(NCCH3)6]2+ species 1 and 2, respectively.  The increased nitrile bond energy for both 
3 and 4 indicates stronger σ-bonding of the bound acetonitriles occurs upon addition of a 
Tp-type ligand.   
 A new complex, [TpPhRu(NCCH3)3][OTf] (5), was also synthesized using this 
new procedure with a yield of 53%.  In the 1H NMR spectrum for 5, two separate 
resonances are now observed for both the ortho and meta protons on the phenyl 
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substituents, indicating that the corresponding protons on the phenyl rings are not 
equivalent.  The 19F{1H} NMR spectrum shows a slight downfield shift to δ -77.7 as 
compared to δ -79.3 for 2, indicating that the triflate counteranion is still not coordinated 
to the ruthenium center, although there may be some competition in binding between the 
triflate and the TpPh ligand.  The IR spectrum of 5 showed an decreased vibrational 
energy for the bound acetonitrile ligands of 2345 cm-1 compared to 2373 cm-1 for 
[Ru(NCCH3)6]2+ species 2, similar to the shift observed for the Tp* analog 4.  This result 
shows stronger backbonding of the acetonitriles to the ruthenium center, even with the 
increased steric bulk on the TpPh ligand.   
Synthesis and characterization of new tris(pyrazolyl)methane-type 
tris(acetonitrile) ruthenium(II) complexes.  Two new complexes of the formula 
[TpmRRu(NCCH3)3]2+ were synthesized using the same improved procedure for 
synthesizing the [TpRRu(NCCH3)3]+ complexes.  Synthesis of 
[Tpm*Ru(NCCH3)3][(BF4)2] (6) and [TpmPhRu(NCCH3)3][(OTf)2] (7) takes only one 
step and 16 h (including work-up) to prepare (Figure 3.9) with yields of 72% and 22%, 
respectively (Table 3.1).  The 1H NMR spectra for 6 and 7 show the same pattern of 
resonances observed for analogous Tp* and TpPh ruthenium complexes, 4 and 5, 
respectively.  As seen for these TpR ruthenium complexes, the resonance for the bound 
acetonitrile ligands shifts downfield (δ 1.60 and 2.62 for 6 and 7, respectively), compared 
to δ 2.68 and 2.52 for the bound acetonitrile in [Ru(NCCH3)6]2+ starting materials 1 and 
2, respectively.  The 13C{1H} NMR spectrum of 6 show similar shifting to the TpR 
analogs 4.  The 19F{1H} NMR spectra for 6 and 7 indicate that the counteranion is not 
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coordinated to the ruthenium center, as their 19F resonances did not shift compared to the 
resonances of the [Ru(NCCH3)6]2+ starting materials.  
 
[Ru(NCCH3)6][(X)2]
TpmR
CH3OH, reflux 18 h
6: R = Me, X = BF4-
7: R = Ph, X = OTf-
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R
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Figure 3.9.  Synthesis of [TpmRRu(NCCH3)3][(X)2]. 
 
   The IR spectra of [(TpmR)Ru(NCCH3)3][(X)2] complexes 6 (R = Me, X = BF4-) 
and 7 (R = Ph, X = OTf-) both show a nitrile stretching frequency of 2345 cm-1, 
compared to 2326 and 2373 cm-1 for [Ru(NCCH3)6]2+ species 1 and 2, respectively.  The 
increased nitrile bond energy for 6 indicates that stronger σ-bonding of the bound 
acetonitrile ligands occurs upon addition of a Tpm* ligand, whereas the decreased nitrile 
bond energy for 7 indicates stronger backbonding of the bound acetonitrile ligands to the 
ruthenium center upon adding a TpmPh ligand.   
Many attempts were made to synthesize [TpmRu(NCCH3)3][(X)2] (X = BF4, OTf) 
without success.  The synthetic procedure outlined in Figure 3.9 was attempted in 
 63
multiple solvents (acetonitrile, methanol, ethanol, THF, dichloromethane, DMF, toluene), 
varying reaction times (4 h to 60 h), and varying temperatures (from room temperature to 
reflux).  All 1H NMR spectra of the reaction mixtures indicated no coordination of the 
Tpm ligand to ruthenium(II). 
 Comparison of the syntheses of tris(pyrazolyl) ruthenium(II) complexes.  The 
data in Table 3.2 clearly shows that synthesis of the reported complexes 3 – 7 require a 
large number of steps and long times, making these synthons less desirable to use in 
ruthenium chemistry than the commonly used synthons such as TpRuCl(COD),17 
TpRuCl(PPh3)2,18 and [TpmRuCl(PPh3)2][BF4]19 (Figure 3.10).  In contrast, complexes of 
the formula [TpRRu(NCCH3)3][X] (R = H, Me, Ph; X = BF4, OTf) synthesized according 
to the new procedure (Figure 3.5) require only one step and 5 h preparation times.  This 
procedure has also enabled synthesis of new TpmR complexes 
[Tpm*Ru(NCCH3)3][(BF4)2]  and [TpmPhRu(NCCH3)3][(OTf)2]  in one step with up to 
16 h preparation times.     
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Figure 3.10.  (Tp)RuCl(COD) (left), (Tp)RuCl(PPh3)2 (middle), and 
[(Tpm)RuCl(PPh3)2][BF4] (right). 
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The reaction times needed to synthesize the TpR (15 min to 1 h) ruthenium(II) 
complexes are surprisingly fast considering the inert nature of ruthenium(II), and they 
follow a trend based on the ligand charge and their steric bulk.  Charged trinitrogen donor 
ligands expectedly require less reaction time than uncharged donors (8 to 12 h for the 
Tpm* and TpmPh complexes, respectively), thus in increasing reaction time, TpPh < Tp* < 
Tp < TpmPh < Tpm*.  The syntheses also decrease in reaction time as the steric bulk of 
the trinitrogen donor is increased in the order TpPh < Tp* < Tp and TpmPh < Tpm*.  
Electrochemistry of ruthenium(II) complexes.  Cyclic voltammetry was performed 
on ruthenium(II) acetonitrile-containing complexes 1 and 3 – 7 to determine how 
changing the charge and steric bulk of the Tp-type ligands affects the Ru2+/3+ redox 
potentials (Table 3.3).  The Ru2+/3+ potentials indicate that the charge on Tp-type ligands 
has a significant effect on Ru2+/3+ electrochemical potentials.  The Tp* analog 4 (0.498 V 
vs. NHE) has a slightly higher potential than its Tpm* analog, 6 (0.390 V), and the TpPh 
analog 5 (0.595 V) has a slightly higher potential than its TpmPh analog 7 (0.552 V), 
indicating that charged Tp-type ligands better stabilize ruthenium(III) relative to 
ruthenium(II).  These results agree with the nitrile bond frequencies for 4 and 6, (2472 
cm-1 and 2345 cm-1, respectively) indicating that σ-donor bonding of the bound 
acetonitriles in 4 is more significant than in 6.       
The Ru2+/3+ potentials in Table 3.3 also indicate that [TpRu(NCCH3)3]+ (3)  has a 
lower Ru2+/3+ potential (0.489 V vs. NHE) than both the Tp* analog 4 (0.498 V) and the 
TpPh analog 5 (0.595 V).  A similar trend of increasing potentials is also observed for the 
neutral Tpm* complex 6 (0.390 V) and the TpmPh complex 7 (0.552 V).  Comparison of  
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Table 3.3.  Ru2+/3+ potentials for target complexes (E vs. NHE). 
 
the Ru2+/3+ potentials of these complexes shows that the steric bulk of analogous TpR-type 
ligands (R = H, Me, Ph) has a modest effect on the redox potential of ruthenium(II), 
stabilizing ruthenium(II) relative to ruthenium(III), where TpPh < Tp* < Tp and TpmPh < 
Tpm*.  A similar trend was also observed for the Tp-type complexes of copper(I) 
complexes of the formula TpRCu(NCCH3) and [TpmRCu(NCCH3)][X] (R = H, Me, iPr; X 
= Cl, BF4).18  Overall, using Tp-type ligands of varying steric bulk can change the Ru2+/3+ 
potential by over 200 mV. 
 Conclusions.  An improved synthetic method has been developed for 
[Ru(NCCH3)6]2+ starting materials and the Tp-type ruthenium(II) tris(acetonitrile) series 
of complexes that only requires one step in the synthetic procedure.  Using a similar 
synthetic pathway, a novel series of Tpm-type ruthenium(II) tris(acetonitrile) complexes 
were synthesized that may be used for comparative purposes with its Tp-type analogs.  
This new synthetic method to synthesize these Tp- and Tpm-type tris(acetonitrile) 
ruthenium(II) complexes will help open up ruthenium chemistry in catalysis and DNA 
Complex Epa (V) Epc (V) ∆E (V) E½, (V) 
[Ru(NCCH3)6][(BF4)2] (1) 0.410 0.623 0.213 0.517 
[TpRu(NCCH3)3][BF4] (3)  0.352 0.625 0.273 0.489 
[Tp*Ru(NCCH3)3][OTf] (4) 0.415 0.580 0.165 0.498 
[TpPhRu(NCCH3)3][BF4] (5) -0.457 1.65 2.11 0.595 
[Tpm*Ru(NCCH3)3][(BF4)2] (6)  0.099 0.681 0.582 0.390 
[TpmPhRu(NCCH3)3][(BF4)2] (7) -0.500 1.603 2.10 0.552 
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binding, where these complexes can be used as synthons. 
Understanding the redox chemistry of ruthenium with nitrogen donor ligands can 
give us insight into how ruthenium complexes behave in biological systems.  
Coordination of Tp-type ligands to ruthenium can significantly alter Ru2+/3+ 
electrochemical potentials from 0.390 V to 0.595 V.  Steric bulk, rather than the charge 
of the Tp-type ligands, is the predominant factor that controls Ru2+/3+ redox potential.   
This ability to stabilize either oxidation state of ruthenium (+2 or +3) may be used to tune 
catalytic reactions and provide insight into how ruthenium may behave when bound to 
DNA. 
 
Experimental Methods 
General air-sensitive techniques under argon were used to synthesize the 
complexes unless otherwise stated.  1H, 13C{1H}, and 19F{1H} NMR spectra were 
obtained using 300 and 500 MHz Bruker-AVANCE NMR spectrometers.  1H and 
13C{1H} NMR chemical shifts are reported in δ relative to tetramethylsilane (TMS) and 
referenced to solvent. 19F{1H} NMR spectra were externally referenced to CCl3F (δ 019).  
Infrared spectra were obtained using Nujol mulls on KBr salt plates with a Magna 550 IR 
spectrometer.  Abbreviations used in the description of vibrational data are as follows: vs, 
very strong; s, strong; m, medium; w, weak; b, broad.  Electrospray ionization mass 
spectrometry (ESI-MS) was conducted using a QSTAR XL Hybrid MS/MS System from 
Applied Biosystems via direct injection of sample (0.05 mL/min flow rate) into a Turbo 
Ionspray ionization source.  Samples were run under positive mode in methanol, with 
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ionspray voltage of 5500 V, and in TOF scan mode.  Peak envelopes match theoretical 
calculations for their ions.   
Elemental analyses were performed in-house on a Perkin Elmer 2400 Series II 
CHNS/O Elemental analyzer.  The elemental analysis for the acetonitrile-containing 
ruthenium complexes (1 – 7) were within 3% of the values calculated for the tetrahedral 
complexes resulting from the loss of two acetonitrile ligands.  This loss of two 
acetonitrile ligands resulted from drying in vacuo for approximately 4 h., as has been 
previously reported for the iron(II) triflate complex.20  
Ruthenium(III) chloride hydrate was purchased from Pressure Chemical; 
potassium borohydride, 3,5-dimethylpyrazole, sodium tetrafluoroborate, and tetra-n-
butylammonium bromide were purchased from Alfa Aesar; diethyl ether was purchased 
from Fisher/Acros; methanol and acetonitrile were purchased from Mallinkrodt; 
chloroform was purchased from BDH; sodium triflate was purchased from TCI; and dry 
methanol was purchased from Burdick.  KTp, KTp*,21 KTpPh,22  Tpm,23 Tpm*,23 and 
TpmPh 24 were synthesized using reported procedures.   
Syntheses of [Ru(NCCH3)6][(BF4)2] (1) and [Ru(NCCH3)6][(OTf)2] (2).  A new 
method was used to synthesize 1.  Zinc powder (0.23 g, 3.60 mmol) was added to a 
solution of ruthenium(III) chloride hydrate (2.0 g, 7.15 mmol) in acetonitrile (150 mL) 
and the mixture was heated to reflux for 30 min.  The mixture turned from black to 
yellow during this time.  The reaction mixture was filtered, sodium tetrafluoroborate 
(1.65 g, 15.0 mmol) was added to the filtrate, and the solution was heated to reflux for an 
additional 12 h, during which time a white precipitate formed.  The solution was again 
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filtered and the solvent was removed in vacuo.  The light yellow powder was washed 
with ether to remove any excess zinc salts.  Crystals of X-ray quality were grown by 
vapor diffusion of diethyl ether into acetonitrile.  Yield: 2.47 g (66%).  The synthesis for 
2 is the same as for 1, except that sodium triflate (2.59 g, 15.0 mmol) was added instead 
of sodium tetrafluoroborate.  Yield: 2.78 g (60%).  1H NMR (d6-DMSO) and IR (Nujol, 
cm-1) spectra of 1 and 2 match reported values.12,21  For 1: 13C{1H} NMR (d6-DMSO):  
δ 4.01 (CH3CN), 126.9 (CH3CN).  19F{1H} NMR (d6-DMSO): δ -148.3 (s).  Anal. Calc. 
for RuC8H10F8N4B2: C, 21.88; N, 12.76; H, 2.74.  Found: C, 22.92; N, 13.32; H, 13.32.  
For 2: 13C{1H} NMR spectrum identical to 1.  19F{1H} NMR (d6-DMSO): δ -79.3 (s).  
Anal. Calc. for RuC10H10S2F6O6N4: C, 21.30; N, 9.94; H, 2.13.  Found: C, 20.64; N, 8.11; 
H, 2.12.  
Synthesis of [TpRu(NCCH3)3][BF4] (3).   We have synthesized this previously 
reported complex13 using our improved method.  KTp (88.1 mg, 0.35 mmol) dissolved in 
methanol (10 mL) was added dropwise using a cannula to a solution of 1 (200 mg, 0.38 
mmol) in methanol (25 mL), and the solution was stirred for 30 min.  A white precipitate 
formed and was separated using cannula filtration.  The filtrate was concentrated by 
reducing the volume of the solvent to 10 mL, and a dull white solid precipitated.  Ether 
(15 mL) was added to facilitate precipitation, and the light yellow powder was separated 
by cannula filtration, washed with ether (10 mL), and dried in vacuo.  Yield: 103 mg 
(56%).  1H and 13C{1H} NMR (d6-DMSO) and IR (Nujol, cm-1) spectra match previously 
reported values.13  19F{1H} NMR (d6-DMSO): δ -148.3 (s).  Anal. Calc. for 
RuC11H13F4N7B: C, 27.39; N, 22.19; H, 2.94.  Found: C, 28.95; N, 20.4; H, 3.05.   
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Synthesis of [Tp*Ru(NCCH3)3][OTf] (4).  We have made this previously reported 
complex14 using our improved method.  Synthesis of 4 is similar to the method used to 
synthesize complex 3, except that [Ru(NCCH3)6][(OTf)2] (2) was used instead of 
[Ru(NCCH3)6][(BF4)2] (1), and KTp* (101 mg, 0.30 mmol) was used instead of KTp.  A 
light yellow powder was obtained after work-up.  Yield: 235 mg (65%).  1H and 13C{1H} 
NMR (d6-DMSO) spectra match previously reported values.14  19F{1H} NMR (d6-
DMSO): δ -77.8 (s).  IR (Nujol, cm-1): 719 m, 759 w, 1048 s, 1110 s, 1207 m, 1261 m, 
1303 s, 1403 s, 1459 s, 1500 m, 2344 w, 2374 w, 2472 m, 2854 s, 2923 s, 3117 w, 3394 
w.  Anal. Calc. for RuC18H25SF3O3N7B: C, 36.73; N, 16.67; H, 4.25.  Found: C, 35.76; N, 
17.65; H, 4.20.   
Synthesis of [TpPhRu(NCCH3)3][OTf] (5).  KTpPh (212 mg, 0.30 mmol) dissolved 
in a 1:1 solution of methanol/acetone (15 mL) was added dropwise using a cannula to a 
solution of 2 (100 mg, 0.30 mmol) in methanol (15 mL), and the solution was stirred for 
15 min, during which time a white precipitate formed.  The reaction was dried in vacuo 
and the residue was extracted with acetone.  The mixture was filtered and the filtrate was 
dried in vacuo to yield a light yellow powder.   Yield: 86 mg (53%).  1H NMR (d6-
DMSO): δ 2.70 (s, 9H, CH3CN), 6.66 (s, 3H, 4-pz), 7.03 (br s, 6H, p-Ph), 7.20 (s, 3H), 
7.31 (t, 6H, m-5-Ph), 7.46 (br t, 6H, m-3-Ph), 7.79 (d, 6H, o-5-Ph), 7.81 (br d, 6H, o-3-
Ph).  19F{1H} NMR (d6-DMSO): δ -77.8 (s).  IR (Nujol, cm-1): 688 w, 754 m, 800 w, 975 
w, 1031 m, 1076 w, 1170 w, 1261 m, 1377 w, 1459 vs, 1655 w, 1686 w, 2345 w, 2373 w, 
2854 vs, 2924 vs, 3448 w.  Anal. Calc. for RuC48H36SF3O3N7B: C, 59.63; N, 10.14; H, 
3.83.  Found: C, 59.75; N, 10.91; H, 3.80.   
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Synthesis of [Tpm*Ru(NCCH3)3][(BF4)2] (6).  Tpm* (119 mg, 0.40 mmol) was 
added to a solution of 1 (200 mg, 0.38 mmol) in methanol (25 mL), and the solution was 
heated to reflux for 12 h.  The reaction mixture was filtered and the solvent was removed 
in vacuo. The residue was washed with ether (10 mL) and dried in vacuo to yield a light 
brown solid.  Yield: 190 mg (72%).  1H NMR (d6-DMSO): δ 1.60 (s, 9H, CH3CN), 2.66 
(s, 9H, 3-Me), 2.72 (s, 9H, 5-Me), 6.33 (s, 3H, 4-pz), 8.09 (s, 1H, Hapi).  13C{1H} NMR 
(d6-DMSO): δ 3.95 (CH3CN), 11.2 (3-Me), 12.0 (5-Me), 67.5 (Capi), 108.2 (C-4), 127.0 
(CH3CN), 143.7 (C-3), 152.9 (C-5).  19F{1H} NMR (d6-DMSO): δ -148.3 (s).  Mass 
spectrum (ESI-MS): m/z 431.2 [(Tpm*)Ru(OMe)]+.  IR (Nujol, cm-1): 724 m, 760 w, 
1058 s, 1282 w, 1377 s, 1459 vs, 2344 w, 2373 w, 2855 s, 2923 s, 3248 w.  Anal. Calc. 
for RuC18H25F8N4B2: C, 35.20; N, 15.97; H, 4.07.  Found: C, 34.57; N, 14.17; H, 3.49.   
Synthesis of [TpmPhRu(NCCH3)3][(OTf)2] (7).  TpmPh (121 mg, 0.30 mmol) was 
added to a solution of 2 (100 mg, 0.30 mmol) in THF (25 mL), and the solution was 
stirred for 8 h at room temperature.  The solution was filtered and the filtrate was dried in 
vacuo.  The residue was extracted with dichloromethane, filtered, and the filtrate dried in 
vacuo to yield a yellow solid.  Yield: 40 mg (22%).  1H NMR (d6-DMSO): δ 2.69 (s, 9H, 
CH3CN), 7.14 (s, 3H, 4-pz), 7.20-7.49 (m, 18H, m-, p-Ph), 7.85-7.91 (m, 12H, o-Ph), 
7.97 (s, 1H, Hapi).  19F{1H} NMR (d6-DMSO): δ -78.8 (s).  IR (Nujol, cm-1): 576 w, 638 
w, 694 s, 761 m, 799 s, 917 w, 954 w, 1028 s, 1094 s, 1261 s, 1377 w, 1459 vs, 1655 w, 
1686 w, 2344 w, 2373 w, 2854 vs, 2924 vs.  Anal. Calc. for RuC50H36S2F6O6N7: C, 
53.75; N, 8.78; H, 3.31.  Found: C, 52.04; N, 8.54; H, 3.83.   
X-ray data collection and structural determination of [Ru(NCCH3)6][(BF4)2] (1).  
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Single crystals of [Ru(NCCH3)6][(BF4)2] were grown from slow vapor diffusion of 
diethyl ether into an acetonitrile solution and were mounted on a glass filament with 
silicon grease and immediately cooled to 168.15 K in a cold nitrogen gas stream. 
Intensity data were collected using a Rigaku Mercury CCD detector and an AFC-8S 
diffractometer. The space group P21/c was determined from the observed systematic 
absences. Data reduction including the application of Lorentz and polarization effects 
(Lp) and absorption corrections used the CrystalClear28 program. The structure was 
solved by direct methods and subsequent Fourier difference techniques, and refined 
anisotropically, by full-matrix least squares, on F2 using SHELXTL 6.10.29  The quantity 
minimized by the least square program was Σw = (Fo2 - Fc2)2 where w = {[σ2(Fo2)] + 
(0.0422P)2 + 1.87P]} where P = (Fo2) + 2Fc2)/3].  In the final cycle of least squares, 
independent anisotropic displacement factors were refined for the non-hydrogen atoms 
and the methyl hydrogen atoms were fixed in “idealized” positions with C-H = 0.96 Å.  
Their isotropic displacement parameters were set equal to 1.5 times Ueq of the attached 
carbon atom.  The largest peak in the final Fourier difference map (0.88 e.Å-3) was 
located 1.61 Å from N1 and the lowest peak (-0.49 e.Å-3) was located at a distance of 
0.86 Å from Ru1.  Final refinement parameters for the structure of [Ru(NCCH3)6][(BF4)2] 
(1) are given in Table 3.4. 
Electrochemical studies of synthesized ruthenium(II) complexes.  Cyclic 
voltammetry (CV) experiments were carried out using CHI Electrochemical analyzer and 
employed a three-electrode cell consisting of glassy carbon working electrode, a 
Ag/AgCl reference electrode, and a platinum wire auxiliary electrode.  The glassy carbon 
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electrode was polished with alumina prior to each trial.  CV experiments were conducted 
in acetonitrile containing 0.1 mM complex and 0.1 M tetra-n-butyl ammonium 
hexafluorophosphate (TBAPF6) at a scan speed of 0.1 V/s from -1.25 V to 1.25 V.  
Solutions were deoxygenated with dry nitrogen gas and maintained under a blanket of 
nitrogen during measurements, and voltammagrams were referenced to the 
ferrocene/ferricenium couple (Fc+/0) at 0.46 V.30  Formal potentials were evaluated as E½ 
= (Epa+Epc)/2, where Epa and Epc are anodic and cathodic peak potentials.  Peak potential 
separations were evaluated as ∆E = |Epa-Epc|.  
 
Table 3.4. Crystallographic data and structure refinement for [Ru(NCCH3)6][(BF4)2] (1). 
Empirical formula   C12H18B2F8N6Ru 
Formula weight (g/mol)  521.01 
Temperature (K)   168.15 
Wavelength (Å)   0.71073 
Crystal system    Monoclinic 
Space group   P21/c 
Unit cell dimensions 
 a (Å)   8.0993(16) 
 b (Å)   8.1969(16) 
 c (Å)   15.877(3)  
 α (deg)   90.00 
 β (deg)   92.78(3) 
 γ (deg)   90.00 
Volume (Å3)   1052.9(4) 
Z    2 
Calculated density (mg/m3)  1.643  
Absorption coefficient (mm-1)  1.048 
F(000)    516 
Crystal size (mm)   0.30 × 0.25 × 0.22 
Crystal color and shape  colorless prism 
Θ range for data collection (deg)                  3.51 < θ < 26.33°  
Limiting indices   -9 < h < 10 
    -10 < k < 10 
    -19 < l < 19 
Reflections collected                    8579 
Independent reflections  2126 
Completeness to Θ   26.33 (99 %) 
Max. transmission   0.8397 
Min. transmission          0.7904 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters                       2126 / 0 / 136 
Goodness of fit on F2                    1.112 
Final R indices (I > 2σ(I)) 
 R1   0.0362 
 wR2   0.0862 
R indices (all data) 
 R1   0.0448 
 wR2   0.0938 
Largest diff. peak and hole                        0.876 and -0.489 e.Å-3 
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Copyright Permission for Figure 1.2 A 
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